OWP Pharmaceuticals Announces FDA Approval To Develop & Commercialize Liquid Formulation Of Antipsychotic Quetiapine Fumarate

OWP Pharmaceuticals, Inc. received approval from the U.S. Food and Drug Administration (FDA) on its Investigational New Drug (IND) application to develop and commercialize a liquid formulation of quetiapine fumarate, an atypical antipsychotic used to treat schizophrenia and bipolar disorder. The liquid form is intended for use by adults with swallowing difficulties or for adults and adolescents who have trouble swallowing tablets or capsules.

The company is a privately held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and commercializing novel liquid oral suspension formulations of approved therapeutics with no currently available liquid formulation. The most recent IND . . .